Shares of Zogenix, Inc. (NASDAQ: ZGNX) traded higher by 200 percent early Friday morning after the company announced top-line results from a phase 3 clinical trial exploring its drug called ZX008 for the treatment of Dravet syndrome.
Zogenix said that its trial met its primary objective of. Read More. Don t Miss Any Updates! News Directly in Your Inbox Subscribe to: